A Manhattan federal appeals court ruled Friday that Bristol-Myers Squibb Co.’s “candid” reaction to a failed clinical trial was not evidence that the pharmaceutical giant and its executives intentionally misled investors about the prospects for a once-promising cancer drug.

The ruling, from a three-judge panel of the U.S. Court of Appeals for the Second Circuit, upheld a lower court’s dismissal of a proposed securities class action, which claimed that Bristol-Myers Squibb made material misstatements or omissions around a clinical trial to determine the drug’s efficacy for treating certain kinds of lung cancers.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]